To the Editor, {#Sec1}
==============

To gain insight into the role(s) of double minute chromosomes (dmins) in leukemia, we cytogenetically/molecularly analyzed 8q24 amplicons in patient-derived leukemic cells and AML-derived cell line (HL60) (See Additional file [1](#MOESM1){ref-type="media"} for supplementary materials and methods). The patient was a 71-year-old female with AML (M2). The G-banding karyotype of leukemic cells was 47, XX, +mar \[2\]/48, XX, idem, +mar \[6\]/46, XX \[7\], containing two marker chromosomes (mars) from chromosome 8 (Figure [1](#Fig1){ref-type="fig"}a and b). DNA copy number analysis (CNA) revealed 13 high-level amplicons on 8q22.1-q24.2 (98.43 Mb-134.16 Mb) (Additional file [2](#MOESM2){ref-type="media"}: Table S1). SKY analysis of HL60 cells containing the 8q24 amplicons revealed that the representative karyotype was 44, X, der(5)t(5;17)(q11.2;q11.2), t(7;16;9)(q34;q24;p21), t(9;14)(q22;q22), +13, -15, -17, der(21)t(15;21)(q22;q21) \[[@CR1]\]. CNA revealed several amplicons on 8q24.13-q24.12 (126.25 Mb-130.75 Mb) in the HL60 cells (Figure [2](#Fig2){ref-type="fig"}a and b). Consequently, three common amplicons were identified between 8q24.13-21 in the patient and the HL60 cells; i.e., the regions covering *NSMCE2* (8q24.13), *PVT1* (8q24.21) and *CCDC26* (8q24.21) (Figures [1](#Fig1){ref-type="fig"}c and [2](#Fig2){ref-type="fig"}b). Further investigation revealed three fusion transcripts between *PVT1* exon 1a and *NSMCE2* exon 3 in the patient (Figure [1](#Fig1){ref-type="fig"}d and e), and a fusion gene between exon 6 of *NSMCE2* and exon 1 of *BF104016*, a noncoding RNA sharing the sequence of *CCDC26* exon 4 (Additional file [3](#MOESM3){ref-type="media"}: Figure S1) (Additional file [4](#MOESM4){ref-type="media"}: Table S2), in the HL60 cells (Figure [2](#Fig2){ref-type="fig"}c-e). Both the *NSMCE2* and *PVT1* genes were amplified and located in a micronucleus in the patient (Figure [1](#Fig1){ref-type="fig"}f-i), and the genomic junction of 5'-*PVT1*-*NSMCE2*-3' was located within intron 1 of *PVT1* and at 5' upstream of exon 1 of *NSMCE2* (Figure [1](#Fig1){ref-type="fig"}j and k) (Additional file [5](#MOESM5){ref-type="media"}: Figure S3). In the HL60 cells, amplification of 3'*NSMCE2* and 5'*CCDC26* was co-localized on der(13)hsr(8), ins(2;8) and dmins (Figure [2](#Fig2){ref-type="fig"}e-h) (Additional file [5](#MOESM5){ref-type="media"}: Figure S3). Aberrant *NSMCE2* transcripts were higher than normal *NSMCE2* transcripts in the patient and the HL60 cells, while NSMCE2 protein expression did not correlate with normal or abnormal *NSMCE2* transcripts among the leukemic patient cells or the HL60 cells, suggesting the presence of regulatory mechanisms other than transcription (Additional file [6](#MOESM6){ref-type="media"}: Figure S2).Figure 1**Identification of** ***PVT1-NSMCE2*** **in the leukemic patient cells. (a)** G-banding analysis. Arrow indicates two marker chromosomes (mars). **(b)** SKY analysis for the patient identified two mars derived from chromosome 8 (arrows). **(c)** Copy number changes at 8q24 detected by high-resolution oligonucleotide array. *NSMCE2*, *TRIB1*, *MYC*, *PVT1*, *CCDC26, GSDMC*, and *FAM49B* are amplified. The direction of the arrows reflects the direction of gene transcription. NG: no gene. **(d)** Detection of three *PVT1-NSMCE2* fusion transcripts by RT-PCR. Primers were P1S and NSMCE2-Ex4AS for 5\'-PVT1-NSMCE2-3\'. Lane Pt.1: leukemic cells from the patient; lane N: water; lane M: size marker. **(e)** Sequence analysis of *NSMCE2* fusion transcript in the patient. **(f)** FISH finding of the patient using *PVT1* probe. Multiple red signals indicate extrachromosomal amplification of 5'*PVT1* on dmins. Co-localized red and green signals indicate normal *PVT1*. Inset shows 5'*PVT1* amplification in a micronucleus equivalent of mar (arrow). (Additional file [5](#MOESM5){ref-type="media"}: Figure S3) **(g)** FISH finding from the patient using an *NSMCE2* probe. Intense yellow signals indicate amplification of *NSMCE2* on mars and co-localized red and green signals signify normal *NSMCE2* on chromosome 8. Inset shows *NSMCE2* amplification in a micronucleus equivalent of mar (arrow). **(h** and **i)** DAPI pictures of metaphase cells corresponding to **(f)** and **(g)**. Arrows indicate mars. In metaphase, *NSMCE2* amplification was detectable on mars. 5'*PVT1* amplification were observed on dmins, however, *PVT1* FISH probe sets could not identify mars because of the background dmins (f and h). **(j)** Results of LDI-PCR. Primers were NSM38374 and NSM38666 for 5\'-PVT1-NSMCE2-3\'. Lane Pt.1: leukemic cells from the patient; lane N: water; lane M: size marker. (Additional file [4](#MOESM4){ref-type="media"}: Table S2) **(k)** Genomic mapping of *PVT1* and *NSMCE2* exons and breakpoint. White vertical boxes represent exons; dotted line represents breakpoint of *PVT1* and *NSMCE2* in the patient detected by LDI-PCR. Horizontal line indicates the location of miRNAs.Figure 2**Identification of** ***BF104016-NSMCE2*** **in HL60. (a)** Representative SKY karyotype of HL60 cells. Arrowheads indicate material inserted from chromosome 8 on ins(2;8) and der(13)hsr(8). Inset shows pseudocolor image of ins(2;8). **(b)** Copy number changes at 8q24 detected by high-resolution oligonucleotide array. *NSMCE2*, *TRIB1*, *MYC*, *PVT1* and *CCDC26* are amplified in HL60. The direction of the arrows reflects the direction of the gene transcription. NG: no gene. **(c)** Bubble PCR products detected by nested PCR using NVAMP1 and NSMCE2-Ex7AS for the first PCR, and NVAMP2 and NSM695 for the second. M: size marker. **(d)** Sequence analysis of *NSMCE2* fusion transcript of HL60. **(e)** Detection of *BF104016-NSMCE2* fusion transcripts by RT-PCR. Primers were BF104-1S and NSMCE2-Ex7AS for 5\'-BF104016-NSMCE2-3\'. Lanes N: water. (Additional file [4](#MOESM4){ref-type="media"}: Table S2) **(f)** FISH finding of HL60 using *CCDC26* probe. Intense co-localized red and green signal indicates amplification of the *CCDC26* gene on der(13)hsr(8) (arrowhead). A co-localized red and green signal is seen on ins(2;8) (arrow). Multiple green signals indicate amplification of the *5'CCDC26* gene on dmins. Co-localized red and green signals show normal *CCDC26*. **(g)** FISH finding of HL60 using *NSMCE2* probe. Intense green signals indicate amplification of 3'*NSMCE2* on der(13)hsr(8) (arrowhead) and ins(2;8) (arrow). Multiple red and green signals indicate amplification of the *NSMCE2* gene on dmins. Co-localized red and green signals indicate normal chromosomal *NSMCE2*. (Additional file [5](#MOESM5){ref-type="media"}: Figure S3) **(h** and **i)** DAPI pictures of metaphase cells corresponding to **(f)** and **(g)**. Arrow and arrowhead indicate ins(2;8) and der(13)hsr(8), respectively.

The present findings are consistent with previous studies demonstrating that segmental genome amplification of 8q24 contains recurrent *PVT1* fusion genes, which might be generated by chromothripsis \[[@CR2],[@CR3]\]. Both lncRNAs, *PVT1* and *CCDC26,* harbor retroviral integration sites and are transcribed into multiple splice forms \[[@CR4]-[@CR6]\]. *PVT1* overexpression is induced by *MYC* or p53, contributing to suppression of apoptosis \[[@CR7]-[@CR9]\], whereas *PVT1* produces six annotated microRNAs that have been implicated in oncogenesis \[[@CR3],[@CR10],[@CR11]\]. The chimeric transcripts involving *PVT1* may also regulate the expression of as-yet unspecified target genes through "enhancer-like functions" \[[@CR12]\]. *CCDC26* amplification has been also identified as a recurrent abnormality that is associated with the response to retinoic acid-induced differentiation in AML \[[@CR1],[@CR11],[@CR13]-[@CR16]\]. This study is the first to identify *NSMCE2*-associated fusion genes in AML \[[@CR17]-[@CR19]\]. Knockdown of *NSMCE2* induces chromosomal instability and increases the frequency of chromosomal breakage and loss \[[@CR20]\]. We speculate that *NSMCE2* gene rearrangement may potentially influence its function. Collectively, our study identified novel *PVT1-NSMCE2* and *CCDC26-NSMCE2* fusion genes that may play functional roles in leukemia.
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**Supplementary material information.**

###### 

CNAG analysis of the region between the *MTDH* and *LRRC6* genes on 8q24 in patient 1 with marker chromosomes. Results show the genomic size of the eight amplified segments that were selected based on the existence of known genes within them and their approximate positions.

###### 

Association between *CCDC26* and *BF104016* at 8q24.21. The scale indicates the region 8q24.21. White boxes and grey boxes indicate exons of *CCDC26* and *BF104016* on the genetic locus at 8q24.21, respecitively. Vertical black lines indicate exons on the *CCDC26* isoform. According to the NCBI database, isoform 1 (BC070152.1) consists of four (1-2-3-4) exons, and isoform 2 (BC026098.1) consists of three (1a-3-4) exons. *BF104016* consists of 2 exons. The sequence of *BF104016* exon 2 is partly consistent with that of *CCDC26* exon 4. ORF: hypothetical open reading frame.

###### 

Sequences of the primers used in this study.

###### 

Identification of breakpoints region at 8q24 by FISH. Upper panel: location of FISH probes shown as color bars and position of *NSMCE2*, *TRIB1*, *MYC*, and *PVT1* genes at 8q24. Vertical black lines indicate exons of *NSMCE2*, *PVT1*, and *BF104016*. Lower panel: mapping of breakpoint in leukemic cells of patient 1 and HL60. Gray boxes indicate amplified regions detected.

###### 

Expression of *NSMCE2* in patient 1 and AML-derived cell lines. (a) *NSMCE2* mRNA levels measured by RQ-PCR (n=3, mean ± SD). Theoretically, the NSMCE2 7-8 primer/probe can amplify both normal and aberrant *NSMCE2* transcripts, while the NSMCE2 2-3 primer/probe set which can amplify only normal *NSMCE2* transcript. *NSMCE2* mRNA levels were normalized to β-actin and are relative to the control mRNA extracted from normal BM cells. *NSMCE2* mRNA levels amplified by the NSMCE2 7-8 primer/probe set are higher than those amplified by the NSMCE2 2-3 primer/probe set in patient 1, HL60 and KG1 cells. (b) Protein analysis using the anti-NSMCE2 antibody in cells. Blot for β-actin was used as loading control. Lane 1: normal BM; lane 2: KG1; lane 3: HL60. (c and d) IHC analysis of NSMCE2 expression in BM of patient 1 (c) and normal BM (d). NSMCE2 expression of leukemic cells was not higher than that of normal BM cells. Monocytes and megakaryocytes showed strong positive signals in their cytoplasm.
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